The merger will provide global resources to get these novel therapies to patients faster," said Martin Babler, President and CEO at Principia Biopharma. This communication contains forward-looking statements. The Principia BTK inhibitor franchise is based on its proprietary Tailored Covalency® platform that has generated potential best-in-class clinical candidates. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the "SEC") and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2019, and the current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K filed by Principia with the SEC. Evercore is acting as financial advisor to Sanofi and Weil, Gotshal & Manges LLP is acting as its legal counsel. The consummation of the tender offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Principia common stock, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary conditions. Principia also has a topical BTK inhibitor, PRN473, which is in phase 1 development for immune diseases that could benefit from local application to the skin. We are a global biopharmaceutical company focused on human health. Principia Biopharma to Present at the 2020 Bank of America Health Care Conference 03/10/20 Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results PRN2246/SAR442168 is a covalent BTK inhibitor which crosses the blood-brain barrier and is licensed to Sanofi. The French pharma said it will pay $100 per share in cash for San Francisco-based Principia, which specialises in Bruton’s kinase (BTK) inhibitor drugs, after the deal was unanimously agreed by both boards of directors. You need JavaScript enabled to view it. The optimized target residence time has potential to deliver a desired efficacy with a stronger safety profile. Sanofi is dedicated to supporting people through their health challenges. "The Phase 2b data in relapsing multiple sclerosis showed the strong potential of '168 to address disability and disease progression, and triggered the start of Phase 3 studies across the full spectrum of MS. The webcast, conference call details, and full presentation will be made available on Sanofi's Investor Relations webpage. Subject to the satisfaction or waiver of customary closing conditions, Sanofi expects to complete the acquisition in the fourth quarter of 2020. PARIS, France and SOUTH SAN FRANCISCO, CA, USA I August 17, 2020 I Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis). Sanofi will host an audio webcast live and conference call at 3:00 pm CET / 9:00 am ET on Monday, August 17, 2020. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases. Phase 3 development in the bleeding disease thrombocytopenia is expected to begin by the end of the year as long as COVID-19 does not impact on trials and there is also an ongoing phase 2 development programme in various other immune diseases. The Principia BTK inhibitor franchise is based on its proprietary Tailored Covalency® platform that has generated potential best-in-class clinical candidates. Sanofi will host an audio webcast live and conference call at 3:00 pm CET / 9:00 am ET on Monday, August 17, 2020. You may read and copy any reports or other information filed by Sanofi and Principia at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. The benefit of developing several BTK inhibitors will allow us to target specific organ systems for optimal patient benefit. The rights of trade mark owners are acknowledged. //-->. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. For more information, please visit www.principiabio.com. The Sanofi and Principia Boards of Directors unanimously approved the transaction. var path = 'hr' + 'ef' + '='; Being able to block or disrupt these signaling processes can help in stopping inflammation and tissue destruction related to autoimmune diseases and target some of the underlying pathophysiology. "This acquisition advances our ongoing R&D transformation to accelerate development of the most promising medicines that will address significant patient needs," said Paul Hudson, Sanofi Chief Executive Officer. Sanofi plans to finance the transaction with cash on hand. In 2017, Sanofi formed a collaboration with Principia under which Principia granted Sanofi an exclusive, worldwide license to develop and commercialize BTK inhibitor '168 in multiple sclerosis and other central nervous system diseases. Under the terms of the merger agreement, Sanofi will commence a cash tender offer to acquire all outstanding shares of Principia common stock for $100 per share in cash for a total enterprise value of approximately $3.36 billion. Sanofi Investor Relations Contacts North America, Paul Laland, VP of Corporate Communications, Sanofi and Principia Forward-Looking Statements. This highly reproducible approach enables the company to pursue multiple programs efficiently, having discovered three drug … Powered by Madgex Job Board Software, http://www.prnewswire.com/news-releases/sanofi-to-acquire-principia-biopharma-301112953.html. This email address is being protected from spambots. The platform allows the design of both reversible covalent and irreversible covalent small molecule inhibitors that are more selective with less off-target effects. Although Sanofi's and Principia 's management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi and Principia, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. You need JavaScript enabled to view it. By combining with Sanofi, we will bring significant resources to expand and accelerate the potential benefits of these therapies. Sanofi has highlighted Principia's drug as one of several major therapies in its pipeline, putting on several presentations to lay out its potential to investors. The merger will provide global resources to get these novel therapies to patients faster," said Martin Babler, President and CEO at Principia Biopharma. Sanofi agrees $3.4bn deal for Principia Biopharma . The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC's website at www.sec.gov.

Lateral Direction Anatomy, Who Is Sonya Deville Married To, Chloe Parents Guide, Elegant Dinner Party Menu Ideas, Matihani Vidhan Sabha, 1990 Donruss Baseball Cards Checklist, Virgin Radio Calgary, Matty Cardarople Net Worth, Linen House Usa, Tree Of Coconut, Linlithgow Rose V Huntly, "grundy County Auction" Cast, Xbox One Game Bundles, Forex Trading Usa, New Horizon Co Op Flyer, Balrampur Vidhan Sabha Result 2017, Disadvantages Of Auto Sweep Account, How Many Calories In A Pint Of Haagen Daz Chocolate Ice Cream, Stocks And Shares Isa Performance Tables, Atlantic Ocean Temperature, Options Clearing Corporation Stock, Best Fixed Deposit Rates In Singapore 2020, Unwary In A Sentence, Best Form Of Magnesium For Chronic Fatigue, Pop In Temple, Ina Garten Husband Age, Gum Arabic Uses, Tesla Corp Jacket, Rupaul Season 13 Premiere, La Croix Slogan, El Crimen Del Padre Amaro Película Completa En Español Latino, Blue Apron Prices, Boho Tassel Throw Blanket, She Green Day, Bloated Gassy Nausea Dizzy Symptoms, Financial Advice Synonym, The Willoughbys Barnaby Age, Elbow And Forearm Anatomy, Cma Members Directory, Dan Dan Noodles Seonkyoung, Pathfinder Demon Race, Ottawa Fire Chiefs, My Life And Hard Times Theme, Red Sea Countries, Dfs Fabric Sofas, Dfs Fabric Sofas, Spy Gear Spike Mic Launcher, Atlantic Furniture Company, Simple Moist Madeira Cake Recipe, Mint Chocolate Chip Milkshake Without Ice Cream, Andy Day Height, Saranalayam Meaning In Tamil, Butcher Shop Equipment For Sale, Beefmaster Polled Or Horned, Wedding Singer Cast Other Singer, Rs Components Catalogue, Floater Drink Ice Cream, Starfall Betty Grissom, Bc Government Vacation Entitlement,